Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUBVENITE vs KEPPRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Treatment of Parkinson's disease as monotherapy or adjunct to levodopa,Off-label: treatment of major depressive disorder (limited evidence)
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing.
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Rasagiline is primarily metabolized by CYP1A2 to its major metabolite, 1-(R)-aminoindan. Minor pathways involve CYP2D6 and conjugation.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Approximately 95% bound to plasma proteins, primarily albumin.
<10% bound to plasma proteins (albumin).
Volume of distribution is approximately 3-7 L/kg, indicating extensive tissue distribution.
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
Oral bioavailability is approximately 50-60%.
Oral: 100% (immediate-release formulation); IV: 100%.
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose by 50%; increase dosing interval to every 12 hours. GFR <15 m L/min: Use not recommended due to accumulation of active metabolite.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
Child-Pugh A (mild): No adjustment. Child-Pugh B (moderate): Reduce starting dose by 50%; titrate cautiously. Child-Pugh C (severe): Avoid use.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
Approved for ages ≥6 years for breakthrough cancer pain: Dose based on prior opioid requirement; typical starting dose 2 mcg/kg sublingually; titrate by 2 mcg/kg as needed; maximum single dose 10 mcg/kg. Maximum 4 doses per day.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
Use with caution; start at lowest available dose (2 mg sublingually). Monitor for increased sensitivity and respiratory depression; titrate slowly.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
No FDA black box warning.
None
Hypertensive crisis with tyramine-rich foods, beverages, or drugs (e.g., sympathomimetics, other MAOIs),Serotonin syndrome when used with serotonergic drugs,May cause hallucinations, confusion, or impulse control disorders,May exacerbate dyskinesia when used with levodopa,Caution in patients with hepatic impairment
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
Concurrent use of other MAOIs (including linezolid or IV methylene blue),Concurrent use of sympathomimetic amines (e.g., amphetamines, cold products),Concurrent use of pethidine, SSRIs, SNRIs, tricyclic antidepressants, or St. John's wort,Pheochromocytoma,Severe hepatic impairment
Hypersensitivity to levetiracetam or any of its components
No significant food interactions. Administer with food to reduce flushing and GI symptoms. Avoid alcohol as it may worsen flushing or liver enzyme elevation.
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies reported, but potential for neonatal adaptation syndrome at delivery.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
Excreted into breast milk; M/P ratio not determined. Due to risk of serious adverse reactions in breastfed infants, breastfeeding is not recommended during therapy.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
No formal studies; due to increased plasma volume and renal clearance in pregnancy, therapeutic effect may decrease. Consider monitoring drug levels or dose adjustment based on clinical response, but no established dosing schedule.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
Subvenite is a brand of dimethyl fumarate, used for relapsing forms of multiple sclerosis. Titrate starting dose to minimize flushing and GI adverse effects. Administer with food to reduce flushing. Monitor absolute lymphocyte count (ALC) regularly due to risk of lymphopenia. Consider PML risk with prolonged lymphopenia. Discontinue if ALC < 0.5x10^9/L for >6 months. Non-enteric coated aspirin 325 mg may reduce flushing severity when taken 30 minutes prior to dose.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
Take Subvenite exactly as prescribed, with or without food. Swallow capsules whole; do not crush or chew.,Flushing and stomach upset are common, especially at start. Taking with food and using aspirin (if recommended) can help.,You may need blood tests to monitor white blood cell counts before and during treatment.,Report any signs of infection (fever, persistent cough, fatigue) or new neurological symptoms.,Do not stop or change dose without consulting your doctor.,Store capsules at room temperature away from moisture and heat.
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUBVENITE vs KEPPRA, answered by our medical review team.
SUBVENITE is a Antiepileptic that works by SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.. KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUBVENITE and KEPPRA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUBVENITE is: Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.. The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUBVENITE and KEPPRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUBVENITE is classified as Category C. First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies r. KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.